Terms: = Ovarian cancer AND BMPR1A, ACVRLK3, 657, ENSG00000107779, P36894, ALK3, CD292 AND Staging
2 results:
1. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Trédan O; Provansal M; Abdeddaim C; Lardy-Cleaud A; Hardy-Bessard AC; Kalbacher E; Floquet A; Venat-Bouvet L; Lortholary A; Pop O; Frenel JS; Cancel M; Largillier R; Louvet C; You B; Zannetti A; Anota A; Treilleux I; Pissaloux D; Houlier A; Savoye AM; Mouret-Reynier MA; Meunier J; Levaché CB; Brocard F; Ray-Coquard I
Gynecol Oncol; 2022 Jan; 164(1):18-26. PubMed ID: 34696892
[TBL] [Abstract] [Full Text] [Related]
2. Fusion imaging in preoperative assessment of extent of disease in patients with advanced ovarian cancer: feasibility and agreement with laparoscopic findings.
Moro F; Bertoldo V; Avesani G; Moruzzi MC; Mascilini F; Bolomini G; Caliolo G; Esposito R; Moroni R; Zannoni GF; Fagotti A; Manfredi R; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2021 Dec; 58(6):916-925. PubMed ID: 33847427
[TBL] [Abstract] [Full Text] [Related]
